Home Blog Page 107

RingConn Gen 3 Smart Ring Opens for Pre-Order: Bringing Vascular Insights to Effortless Everyday Wear

World’s Leading Provider of Cutting-Edge Smart Ring Solutions

NEW YORK, May 10, 2026 /PRNewswire/ — RingConn opened Gen 3 pre-orders on May 5th ahead of its official May 29th launch, marking the occasion with a feature on the iconic One Times Square billboard in New York City on the first day of pre-orders. The next-generation device combines holistic health tracking, subtle smart alerts, and new premium finishes, delivering an ultra-lightweight and slim design without compromising long battery life. To celebrate the launch, customers who pre-order through the official RingConn website can enjoy a limited-time 10% discount.*

RingConn Gen 3 featured at One Times Square
RingConn Gen 3 featured at One Times Square

Vascular Trend tracking

RingConn Gen 3 Smart Ring introduces advanced vascular insights, designed to help users observe long‑term vascular trends through continuous data collection.*

Built on over a decade of research in vascular algorithms and modeling, RingConn’s vascular capability moves beyond single-point measurements to long-term trend-based assessment. The system requires periodic user calibration to ensure improved accuracy, with recommendations for calibration three times within the first 24 hours and monthly thereafter. By combining user-input blood pressure data with ring-derived vascular load indicators, the system provides a more comprehensive view of overall vascular health.

Once calibrated, Gen 3 enables automatic vascular load assessments during periods of sleep or low motion, allowing users to continuously track meaningful changes over time without frequent manual input. The system also incorporates key influencing factors—including circadian rhythm adaptation, sleep respiratory health, post-exercise vascular recovery, and overall daily vascular stability—to help users better understand the relationship between lifestyle and cardiovascular patterns.

RingConn Gen 3 vascular trend tracking interface
RingConn Gen 3 vascular trend tracking interface

5 Designs of RingConn Gen 3
5 Designs of RingConn Gen 3

Effortless 24/7 Wearability with Extended Battery Life

RingConn Gen 3 Smart Ring is designed for continuous and comfortable wear, with a fully upgraded experience centered on durability and long-term usability. Featuring a refined ultra-lightweight form factor and enhanced engineering design, the device is built to seamlessly integrate into daily life, enabling consistent and uninterrupted health data tracking.

Powered by RingConn EcoPower Tech 2.0, the Gen 3 features an upgraded battery system and improved energy density, delivering up to 11–14 days of battery life in standard usage without vibration mode. This reduces charging frequency and supports continuous, long-term health monitoring with minimal interruption.

The ring adopts RingConn’s proprietary ergonomic design, resulting in a lighter and thinner profile that conforms more naturally to the finger. With IP68 water resistance up to 100 meters, the Gen 3 is designed for durability in everyday use, enabling reliable performance across a wide range of real-life scenarios. Together, these features allow users to wear the device seamlessly through typing, handwashing, showering, swimming, and sleep – ensuring uninterrupted physiological data collection day and night.

A refined brushed finish, achieved through an advanced laser-engraving process, enhances the device’s surface texture with greater precision and depth. The upgraded finishing process requires over 30% more production time compared to conventional methods, reflecting a higher level of craftsmanship. Expanded color options further enhance versatility, allowing the ring to blend naturally into both casual and professional environments while encouraging consistent daily wear.

Holistic Health Tracking

RingConn Gen 3 Smart Ring delivers comprehensive health tracking across multiple key dimensions, including sleep, sleep apnea, heart rate, blood oxygen, activity, stress, and women’s health management such as menstrual cycle tracking and pregnancy preparation-related insights. Through continuous monitoring and long-term analysis, the device provides users with a more complete understanding of their health status over time, supporting more informed daily lifestyle decisions.

The system is powered by an advanced VCSEL infrared sensing solution, designed to enhance data stability and accuracy across a wide range of wearing conditions and real-world scenarios, strengthening the foundation for long-term health trend analysis. In internal testing, the system achieved a resting heart rate accuracy of ≥98.58%, a blood oxygen mean absolute error (MAE) of ≤0.95%, a step count accuracy of ≥97.20%, and a temperature accuracy of ±0.08°C, demonstrating strong performance in multi-dimensional health data capture.

Subtle Smart Alert

RingConn Gen 3 Smart Ring introduces subtle smart alerts to provide timely feedback when key health changes are detected. Through gentle vibration-based notifications, the device can also prompt users in scenarios such as prolonged inactivity or low battery, helping support more balanced daily usage and awareness. In quiet environments — such as during meetings or conversations — these silent notifications allow users to stay informed without disruptive sounds or attention-grabbing screen notifications.

The alert system is fully customizable, allowing users to enable or disable notifications based on personal preference. By prioritizing minimal disruption and silent vibration cues over intrusive alerts, RingConn ensures that health reminders remain discreet, context-aware, and seamlessly integrated into everyday life.

*Pre-order offer: The 10% limited-time discount is available exclusively at the RingConn official website from May 5 through June 10, 2026.

*This product is not intended to diagnose, treat, cure, or prevent any disease or medical condition. As a pre-diagnostic tool, the Gen 3 does not replace the diagnosis or treatment by a qualified healthcare professional.

For more information or to place a pre-order, visit:
https://bit.ly/ringconngen3 

Follow RingConn on social media:
Instagram: https://bit.ly/ringconninstagram 
TikTok: https://bit.ly/ringconntiktok 

About RingConn

Established in 2021, RingConn is a user-centric company, driven by continuous innovation, to provide professional, continuous, and thoughtful health monitoring products and services. RingConn is dedicated to becoming users’ most trusted guardian for their physical and mental well-being.

11 Lao Nationals Arrested in Indonesia Over Illegal Online Gambling Network

Indonesian police unveiled and raided the operational location of 75 online gambling sites managed by 321 foreign nationals in West Jakarta. 9 May 2026. (Photo credit: Tempo.co)

Eleven Lao nationals are among 321 foreign nationals arrested in Indonesia after authorities raided a major illegal online gambling operation in Jakarta on 9 May, in one of the country’s largest crackdowns on illegal digital betting networks.

According to local media reports, authorities found the suspects operating out of an office building near Jakarta’s Chinatown district, running at least 75 online betting platforms targeting foreign customers outside Indonesia. The operation had been active for approximately two months.

The majority of those arrested were Vietnamese nationals at 228, followed by 57 Chinese, 13 from Myanmar, 11 from Laos, five from Thailand, and three from Cambodia. 

Most suspects had entered Indonesia on short-term visitor visas and overstayed their permits, working in structured roles covering customer service, telemarketing, and financial administration. Authorities confirmed that most were fully aware they had travelled to Indonesia specifically to run gambling operations.

Of the 321 arrested, 275 have been formally charged with violating Indonesia’s criminal code on gambling, which carries a maximum sentence of nine years in prison, along with potential money laundering and immigration charges and fines of up to IDR 2 billion (USD 116,000).

All 11 Lao nationals remain in Indonesian custody pending legal proceedings, while Indonesian authorities coordinate with the Lao embassy on their cases.

The Jakarta raid was the second major roundup of foreign nationals in two consecutive days. 

A day earlier, immigration authorities arrested 210 foreign nationals on Batam Island in connection with a separate online investment scam. Authorities have also recently dismantled similar operations in Surabaya, Bali, and Batam, pointing to an expanding pattern of transnational cybercrime across Indonesia.

The Same Problem Closer to Home

The issue is not confined to overseas operations. 

In late March, Lao authorities dismantled an illegal online gambling network across three districts in the northern province of Houaphanh, arresting 231 people, including 223 Vietnamese nationals and eight Lao citizens. The network used social media platforms and gambling websites to livestream activities to cross-border audiences. 

Officials classified the case as transnational crime and urged the public to report suspicious gambling activities.

Hisense Kicks Off FIFA World Cup 2026™ Campaign, Bringing Fans Closer Through “Innovating a Brighter Life”

QINGDAO, China, May 10, 2026 /PRNewswire/ — Hisense, a leading brand in global consumer electronics and home appliances, today released its latest TV commercial celebrating the upcoming FIFA World Cup 2026TM, kicking off a new campaign that captures the emotional power of football while making its vision of Innovating a Brighter Life real.


From grassroots pitches to living rooms filled with anticipation, the TVC captures moments of joy, resilience, and unity—showing how football creates emotional bonds that transcend age, culture, and geography.

By expanding the narrative from individual growth to collective experience, Hisense positions itself as more than a sponsor—an enabler of meaningful moments. Its RGB MiniLED technology brings this to life through “Natural and Real Color,” delivering ultra-high color gamut and precise reproduction so every moment feels vivid and true to the pitch.

Building on this commitment to authenticity and precision, Hisense will serve as the Official and Exclusive VAR Review TV Provider for the FIFA World Cup 2026TM. In this role, Hisense has equipped the FIFA World Cup Video Operation Room (VOR) with advanced RGB MiniLED displays, enabling video assistant referees to review match footage with clarity, accuracy, and true-to-life color detail.

Hisense has a long history of celebrating the “beautiful game,” having been a global sponsor of multiple FIFA World CupsTM, a partner of three UEFA European Championships, and an Official Partner of the FIFA Club World Cup 2025TM, with a continued presence at the FIFA World Cup 2026TM. This ongoing collaboration underscores how Hisense’s innovations bring fans closer to the action, elevating both the spectacle and the emotion of the sport worldwide.

With this FIFA World Cup 2026TM TVC, Hisense continues to transform global attention into emotional connection—uniting audiences through football and inspiring brighter lives.

Click here for Innovating a Brighter Life together: https://youtu.be/NDKXdcu01bM?si=cUlpwsu7wbYlPYn8

About Hisense

Hisense, founded in 1969, is a globally recognized leader in home appliances and consumer electronics with operations in over 160 countries, specializing in delivering high-quality multimedia products, home appliances, and intelligent IT solutions. According to Omdia, Hisense ranks No. 1 globally in the 100-inch and over TV segment (2023-2025). As The Origin of RGB MiniLED, Hisense continues to lead the next-generation RGB MiniLED innovation. As the official sponsor of the FIFA World Cup 2026TM, Hisense is committed to global sports partnerships as a way to connect with audiences worldwide.

Study pinpoints 45 years as the critical threshold for a significant downturn in male fertility

BEIJING, May 10, 2026 /PRNewswire/ — Forty-five years has been identified as the critical age threshold at which elevated sperm DNA fragmentation significantly reduces fertility potential in men.

High levels of DNA fragmentation, defined as a breakdown of genetic material inside sperm cells, make it harder for sperm to fertilise an egg with other potential adverse outcomes including impaired embryo development and higher miscarriage rates.

Advanced age is an established risk factor for elevated sperm DNA fragmentation with existing studies suggesting a gradual rise as men get older, but the specific age at which it exceeds the clinical brink has been poorly defined.

However, new research presented at the 2026 Congress of the Asia Pacific Initiative on Reproduction (ASPIRE) in Beijing has revealed the age group in which the high-risk threshold is crossed.

Clinical embryologist Ms Yixin Seow said 45 to 49-year-old men had been identified as the age group when a significant rise in sperm DNA fragmentation occurs compared to all younger cohorts.

Her research team conducted a retrospective analysis of sperm DNA fragmentation records at a major Malaysian fertility centre with 249 subjects stratified into five age groups from 30 years to 50-plus years.

“The outcome confirmed gradual increases in DNA fragmentation across the age groups, but most noticeably from age 45, after which it plateaus with minimal further increase in men over the age of 50,” Ms Seow said.

“While larger prospective studies are warranted, our research has clearly shown the age group where there is marked downturn in fertility potential.

“We recommend counselling of patients participating in assisted reproductive technology about the potential impact of advancing male age on likely success of conception and ongoing pregnancy

“Additionally, men aged 45-plus should consider sperm DNA fragmentation testing.”

Infertility affects one in every six couples around the world. It is defined as the failure to conceive after a year of unprotected intercourse, or the inability to carry pregnancies to a live birth. The causes of infertility are equally shared between male and female partners.

The ASPIRE Congress at the China National Convention Centre in Beijing has attracted almost 3,000 scientists, clinicians, nurses and counsellors specialising in assisted reproduction.

It has cast a global spotlight on fertility health in the Asia Pacific region which, like other parts of the world, is experiencing a disturbing downturn in fertility rates.

ASPIRE is a unique Asia Pacific taskforce of specialists in the management of fertility and assisted reproductive technology, and it is dedicated to advancing access to quality treatment for those experiencing infertility across the region.

For further information on the ASPIRE 2026 Congress, go to https://www.aspire2026.com

[Yeahmobi Insight] One in Six People Now Uses AI: A Turning Point for Global Advertising Strategies

XI’AN, China, May 10, 2026 /PRNewswire/ — Recent findings from Microsoft’s 2025 Global AI Adoption Report show that personal AI usage worldwide has reached 16.3%, meaning approximately one in six people now incorporates AI tools into daily life or work. According to Yeahmobi, this shift signals more than growing technology adoption — it reflects a major change in consumer expectations, content behavior, and global advertising strategy.

Yeahmobi noted that AI adoption is evolving differently across mature and emerging markets, creating distinct challenges and opportunities for international advertisers.

In mature markets such as the United States and Western Europe, consumers have largely moved beyond the “what is AI” phase and entered a stage focused on practical productivity applications. AI tools are increasingly being used for tasks such as content creation, reporting, design support, and workflow automation.

As a result, advertising strategies centered on basic AI functionality — such as “AI-generated copy” or “one-click image generation” — are becoming less compelling. Instead, performance-driven messaging focused on measurable outcomes and efficiency gains is resonating more strongly with audiences.

In contrast, emerging markets across Southeast Asia are still experiencing an earlier stage of AI adoption. Countries including Vietnam, Thailand, and Indonesia continue to see rising AI usage, with many consumers interacting with AI tools for the first time. In these markets, users are typically more focused on immediate, practical value, such as writing emails, generating social content, or supporting education and day-to-day productivity.

Yeahmobi believes this divergence is reshaping international advertising strategy in two key ways:

  • In mature markets, advertisers are shifting from feature-focused messaging toward ROI, productivity, and vertical-specific use cases targeting professional audiences;
  • In emerging markets, successful campaigns are increasingly centered on relatable use cases, accessibility, and lowering barriers to first-time adoption.

The company also emphasized that localization now extends far beyond translation. Effective campaigns increasingly rely on local cultural context, social trends, and native communication styles rather than direct adaptation of English or Chinese-language creative assets.

According to Yeahmobi, the next phase of global AI adoption will require advertisers to balance efficiency-driven messaging in developed markets with accessibility and opportunity-driven narratives in emerging regions.

About Yeahmobi
Yeahmobi is a global digital marketing platform focused on programmatic advertising, user acquisition, and AI-powered growth solutions for international brands.

Forward-Looking Statements
This press release contains forward-looking statements. Actual results may differ materially due to various risks and uncertainties. The company undertakes no obligation to update any forward-looking statements.

 

Emotional burden of infertility can undermine lifestyle choices that may help women conceive

BEIJING, May 10, 2026 /PRNewswire/ — The emotional burden of infertility actively undermines the capacity of many women to make sustained lifestyle changes, including weight loss and physical activity, that can improve their chances of becoming pregnant.

A global conference on assisted reproduction in Beijing heard today that the gap between lifestyle recommendations and action among women suffering the emotional stress of infertility was not a matter of willpower, rather a matter of psychology.

Infertility affects one in every six couples worldwide with the causes equally shared between men and women. Professor Anuja Dokras, an internationally renowned researcher and patient advocate in fertility health, said up to 60 per cent of affected women experience mental health challenges including anger, sadness, isolation, shame and guilt.

“Yet only about 20 per cent of them seek professional psychological support,” she told the 2026 Congress of the Asia Pacific Initiative on Reproduction (ASPIRE).

“Most of these women internalise blame for their inability to conceive and shame predicts emotional eating and health care avoidance.

“Women seeking fertility treatment show significantly higher levels of anxiety, depression and psychiatric disorders than men, and the severity of these conditions is influenced by the cause and duration of infertility, the treatment type and number of failed IVF cycles.”

Professor Dokras is the Executive Director of the Women’s Health Centre for Clinical Innovation and the Founder’s Professor of Women’s Health in the Department of Obstetrics and Gynaecology at the University of Pennsylvania, Philadelphia. She is also the Director of the PENN Polycystic Ovary Syndrome (PCOS) Centre and specialises in understanding cardiometabolic risk and mental health co-morbidities associated with PCOS.

Professor Dokras said women who were obese or living with metabolic disorders associated with PCOS had significantly lower chances of conceiving than their healthy counterparts.

“In women with PCOS visible symptoms, including hirsutism and weight gain, intensify the dynamics of weight stigma with increased prevalence of disordered eating, anxiety and depression.

“Critically, the clinical encounter itself can reinforce barriers when lifestyle advice is delivered through a weight-centric lens without psychological scaffolding.

“A weight-centric consultation approach is perceived as stigmatising and counterproductive. Clinicians should speak the language of self-care, not weight targets.”

Professor Dokras said evidence-based, integrated lifestyle and psychological support was vital in helping women to overcome barriers to better outcomes in fertility treatment.

“Evidence from randomised controlled trials supports the integration of cognitive behavioural therapy and mindfulness-based interventions alongside lifestyle programs,” she explained.

“They demonstrate significant reductions in depression, anxiety and infertility-specific distress as well as improved quality of life.

“Effective support requires reframing lifestyle change as self-care, screening routinely for psychological distress throughout the treatment cycle, avoiding stigmatising language, and embedding mental health provision within fertility services as standard practice.”

Around 3,000 specialists in fertility health – including scientists, clinicians, nurses and counsellors – are attending the ASPIRE Congress at the China National Convention Centre in Beijing.

For further information, go to https://www.aspire2026.com

ACROBiosystems Launches Global License Solution Upgrade for HEK293 Functional Cell Lines, Streamlining Compliance to Accelerate Biopharmaceutical R&D

NEWARK, Del., May 10, 2026 /PRNewswire/ — ACROBiosystems has implemented a major upgrade to its global licensing framework for HEK293 functional cell lines, transitioning from a complex administrative process to a streamlined, purchase-based authorization model. This policy shift addresses the industry-wide challenge of compliance delays by embedding intellectual property clearance directly into the procurement process, thereby empowering global biopharmaceutical innovation with a more efficient and barrier-free R&D experience.

The official statement reads as follows:

  • Preface

The innovative development of biopharmaceuticals relies on stable, legally compliant R&D tools. Functional cell lines serve as a versatile vital engine driving full-cycle breakthroughs in innovative drug R&D, and the ease of obtaining usage authorization for functional cell lines directly impacts projects timelines. To simplify compliance arrangements and reduce administrative burdens for global partners, ACROBiosystems has upgraded its global permitted use policy for HEK293 functional cell line products. The updated framework provides an expansive scope of usage rights to encompass not only internal research but also certain activities from early discovery well into clinical development. It provides clear and standardized legitimate usage scopes and removes redundant review steps, enabling researchers to conduct R&D activities in full compliance with IP and contractual requirements. Customers operating within the defined permitted use scope are now exempt from additional license processing and associated cost, allowing them to focus on core drug R&D and accelerate project progress, with greatly improved efficiency.

  • Core Policy & Compliance Framework

The upgraded policy simplifies compliance processes while establishing clear legitimate usage boundaries. Customers operating within the defined permitted use scope below are entitled to utilize HEK293 functional cell line products for specified activities without additional application or approval.

1.Permitted Usage Scope

HEK293 functional cell line products are authorized for use in internal research, drug discovery, assay development, internal quality assurance (QA) testing and lot release analysis.

*Note: For all other commercial uses beyond the above scopes, customers shall contact ACROBiosystems to obtain a license through flexible options.

2.Regional & Usage Notes

This policy applies to all global markets except the Greater China region, delivering seamless, efficient access to the HEK293 functional cell line products for research and development activities. By eliminating unnecessary administrative hurdles, this streamlined compliance approach empowers global researchers to redirect their focus toward core R&D priorities—rather than navigating complex compliance procedures.

For users in the Greater China region, the HEK293 functional cell line products are permitted for research use only, with separate official authorization required for any extended usage needs.

  • Global Localized Support

With localized teams across the United States, Europe and the Asia-Pacific area, ACROBiosystems provides dedicated policy guidance and one-stop compliance consulting tailored to this HEK293 functional cell line global license upgrade. Our regional experts offer timely interpretation of updated usage rules, streamlined consultation for scope expansion requests, and professional technical backing, helping global customers quickly adapt to the new policy and carry out functional cell line-related R&D in a fully compliant, efficient manner.

  • Conclusion

This policy upgrade further clarifies global permitted-use terms for HEK293 functional cell line products, streamlines daily compliance management, and lowers overall operational and compliance costs for global drug developers. By establishing a clearer, more flexible global compliance framework, ACROBiosystems enables the standardized, orderly and scalable expansion of HEK293 functional cell line compliant applications across diverse R&D scenarios. Moving forward, we will continue to optimize global IP governance and licensing mechanisms, deliver regulated, transparent and user-friendly functional cell line solutions, and support customers in exploring broader preclinical and translational research possibilities with fully compliant functional cell line resources, jointly accelerating high-quality innovative drug development worldwide.

About ACROBiosystems Group

ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and healthcare industries by providing innovative products and business models. The company spans across the globe and maintains offices, R&D centers, and production bases in more than 15 different cities within the United States, Switzerland, the United Kingdom and Germany. ACROBiosystems Group has established numerous long-term and stable partnerships with the world’s top pharmaceutical enterprises, including Pfizer, Novartis, and Johnson & Johnson, and numerous well-known academic institutes. The company comprises several subsidiaries such as ACROBiosystems, bioSeedin, Condense Capital, and ACRODiagnostics.

ACROBiosystems’ brands include Resilient Supply, CytoPak, SAFENSURE, FLAG, Star Staining, Aneuro, ComboX, GENPower and many others. Its main products and services are recombinant proteins, kits, antibodies, scientific services, and other related products. ACROBiosystems employs a strict quality control system for its products that are used in biopharmaceutical research and development, production, and clinical application. This includes targeted discovery and validation, candidate drug screening/optimization, CMC development and pilot production, preclinical research, clinical trials, commercial production, and clinical application of companion diagnostics.

Through the continuous development of new technologies and products, ACROBiosystems Group creates value for the global pharmaceutical industry and actively empowers our partners. The company is dedicated to accelerating the drug development process, including targeted therapies, immunotherapeutic drugs, and their clinical applications, and contributes to global health.

ACROBiosystems HEK293 Cell Line Products (Partial)
ACROBiosystems HEK293 Cell Line Products (Partial)

 

MimiSilk Celebrates Mother’s Day 2026: The Gift of Skin Confidence

MONROE, N.J. and RANCHO CUCAMONGA, Calif., May 9, 2026 /PRNewswire/ — MimiSilk, the clinical-grade at-home beauty device brand, launched its 2026 Mother’s Day campaign, offering a limited-time promotion across its full product collection. The campaign aims to provide consumers with accessible, professional skincare solutions as a gifting choice for the holiday, offering mothers a way to experience medical-grade skin rejuvenation from the comfort of home.

MimiSilk's 2026 Mother's Day campaign
MimiSilk’s 2026 Mother’s Day campaign

About MimiSilk: Silk Your Skin, Love Your Glow

MimiSilk was founded on a clear mission: to make clinical-grade skincare part of everyday life — offering an effective standalone solution for those seeking skin rejuvenation at home, and a powerful complement to in-clinic treatments for long-term maintenance and lasting results. Its devices are designed to be safe, accessible, and built into daily life – supporting women in building consistent self-care habits that help soften visible signs of aging, restore a natural inner glow, and achieve a texture as smooth as silk. At the core of the brand is a simple belief: beauty is about confidence, control, and taking time to care for yourself.

MimiSilk Iris: Multi-Benefit Anti-Aging in One Device

The flagship product of this season’s campaign is the MimiSilk Iris, a non-ablative fractional laser device for at-home use. Operating at a clinically proven 1450 nm wavelength, Iris stimulates natural collagen production to address the appearance of wrinkles, refine pore visibility, and improve overall skin radiance. The device is non-invasive and requires no recovery downtime, making it compatible with a standard nightly skincare routine.

A Limited-Time Mother’s Day 2026 Offer

The Mother’s Day promotion is available across MimiSilk’s collection, catering to both individual consumers and gift shoppers, making it a practical gifting choice for those looking to offer a practical, results-oriented skincare solution.

MimiSilk believes skincare can be more than a beauty step — it can be a meaningful part of how women feel refreshed, confident, and cared for in daily life. A few focused moments each week can become a quiet ritual of restoration and self-care. This Mother’s Day and beyond, the brand hopes mothers everywhere feel seen, appreciated, and beautifully radiant.

Further details on the campaign and products are available on the MimiSilk official website.